Reality checks archive
Every hot take, fact-checked.
49 articlesseparating internet hype from what the evidence actually shows. Filter by category, sort by what’s newest, see the evidence tier on every card.
The Libido Peptide Everyone Calls PT-141 Has Been an FDA Drug Since 2019. The Gap Is the Story.
PT-141 has been FDA-approved since 2019 as Vyleesi — and the 2026 compounding wave that reshaped peptide access did not change that.
CagriSema Has a New FDA Filing and ADA 2026 Data. The Half That Isn't Semaglutide Does the Explaining.
The amylin analog inside Novo Nordisk's next weight-loss drug just showed up in the NEJM at ADA 2026 — and it's not semaglutide.
TB-500 Made the FDA's July 23 Docket. The Recovery Stack Claims Didn't Make the Evidence List.
TB-500 is on the July 23 FDA compounding docket — and the oral comment window closes in three days with the recovery claims still unproven.
Semax Got a July FDA Hearing Date. The Nootropic Claims Aren't the Agenda.
The ACTH-fragment peptide from Russia just made the FDA's July 24 compounding docket — and the committee is reviewing a pharmacy-access question, not a cognitive-enhancement claim.
MOTS-c Just Made the FDA's July Docket. The 'Exercise Peptide' Frame Has a Problem.
The mitochondrial peptide trending as exercise-in-a-vial just made the FDA's July 23 agenda — but regulators are asking about obesity and osteoporosis, not athletic optimization.
Sermorelin Escaped the 2023 Peptide Purge. FDA Attestation Rules in 2026 Found It Anyway.
Sermorelin survived the 2023 compounding crackdown by not being on the restricted list. In 2026, new FDA attestation rules found it anyway.
Fifty Years of BPC-157 Animal Data Just Got an FDA Hearing Date. The Human Trials Are Still Missing.
STAT News profiled BPC-157's creator this month — the FDA's July 23 review finds five decades of animal data and no human trials.
Compounded Semaglutide Ends This Week. Medicare's Version Starts Next.
The FDA's June 29 deadline ends compounded semaglutide's legal pathway — and nine days later, Medicare opens Wegovy at $50 a month.
Epitalon Got a July FDA Hearing Date. The Committee Is Asking About Sleep, Not Telomeres.
The biohacking peptide that promises telomere extension just made the FDA's July PCAC docket — and the committee is reviewing it for insomnia, not anti-aging.
Ipamorelin Just Got Off the FDA's Banned List. The Evidence Stayed Behind.
Ipamorelin cleared the FDA's compounding restriction in April 2026 — three years after the ban, with fewer human trials than its forum reputation suggests.
GHK-Cu Is All Over Sephora This Month. The Peptide Biology Is Actually Real.
The copper tripeptide driving 2026's beauty boom just cleared the FDA's compounding ban, and the science behind the serum is worth reading.
Saxenda Got a Generic. ENDO 2026 Just Told Us What GLP-1s Actually Do to Exercise.
The original weight-loss GLP-1 just got a generic — and the ENDO 2026 study about exercise levels applies to every drug in this class.
Retatrutide Isn't Approved. A CBS Investigation Just Found 120 Clinics Prescribing It Anyway.
CBS News this week found 120+ clinics prescribing the unapproved triple-agonist — while ADA Phase 3 safety data landed in the Lancet.
Tirzepatide Drops Pounds. A June Trial Just Measured the Muscle Going With Them.
A phase 2 trial in Nature Medicine this week showed 30% of tirzepatide weight loss is lean mass — and the drug that cut that in half had no effect on strength.
TB-500 Got a Research Stack and a July FDA Date. Thymosin Beta-4 Has a Different Evidence Story.
A June 11 research stack and a July FDA hearing both invoke thymosin beta-4 — but its evidence runs to different places than the forum history suggests.
GHRP-6 Is Still Banned by the FDA. Its Entire Peer Group Just Got Out.
Fourteen peptides cleared the FDA's restricted list in February. GHRP-6 did not, and the reason involves the approved growth hormone category.
Thymosin Alpha-1 Is Approved in 35 Countries. The US Keeps Missing the Meeting.
Zadaxin is approved in 35 countries and just appeared in June fertility research — the US compounding vote went the other way in December.
Everyone's Posting the Melanotan Tanning Shot. The FDA-Approved Version Has a Completely Different Job.
A self-injection video went viral this week showing five months of Melanotan-II use — while the approved melanocortin drug just got a quiet FDA win.
Everybody's Tracking GLP-1 Drugs. The Peptide That Started It All Just Had Its Best ADA Week in Years.
Inhaled insulin just got FDA-approved for children, and ADA 2026 pharmacokinetic data this week shows it outperforming lispro on onset.
IGF-1 LR3 Is Everywhere on TikTok. The Human Evidence Is Not.
The bodybuilding peptide with millions of views this month borrows its biology from insulin-family signaling — and has no completed human randomized trial behind the muscle claims.
KPV Just Got Off the FDA's Restricted List. The Gut-Health Case Wasn't Part of It.
The tripeptide cleared the FDA's restricted list in February and earned a July review date — but the committee's question is about wound healing, not IBD.
GLP-1 Just Got Recommended for Type 1 Diabetes. The Hormone Behind Ozempic Is the Part Nobody Explains.
The ADA's 2026 Standards just added GLP-1 therapy to Type 1 diabetes treatment — and the native hormone behind Ozempic finally gets explained.
Tirzepatide Keeps Beating Semaglutide. GIP Is the Part Nobody's Explaining.
A dedicated GIP and GLP-1 mechanisms symposium opens at ADA 2026 this week — here's the biology behind tirzepatide's edge that most explainers skip.
SS-31 Searches Spiked 47% This Month. The First FDA-Approved Mitochondria Drug Has Been Out Since September.
The mitochondria peptide the longevity community has been chasing for years became an FDA-approved drug last September — for an ultra-rare disease affecting roughly 150 people.
The 24% Weight-Loss Drug Just Got a New Name at ADA 2026. The Phase 3 Story Is More Complicated.
Amycretin got an official INN at ADA 2026 this week — and the Phase 3 behind the 24% number that broke the internet is now enrolling.
The FDA Put Semax on the July Docket. Selank Searches Just Spiked 31% Anyway.
Semax earned a formal FDA review date for July — its nootropic twin Selank is absent from both PCAC lists, and monthly searches just hit +31%.
Survodutide's Phase 3 Results Are In. ADA 2026 Opens in Five Days. The Lean Mass Data Is the Real Story.
Survodutide's Phase 3 results landed last month, ADA 2026 opens June 5, and the lean mass finding is why this one isn't just another GLP-1 drug.
CJC-1295 Is Off the Restricted List. The FDA's July Review Went to Everyone Else.
The most prescribed GH peptide in American clinics cleared the FDA's Category 2 ban this spring — and still has no formal review date before July.
Pemvidutide Is Everywhere as the 'Muscle-Safe' GLP-1. The EASL Data Yesterday Is About Your Liver.
Altimmune dropped 48-week liver fibrosis data at EASL 2026 yesterday — and the wellness community was watching for a completely different number.
Melanotan-II Got 27 Fines in Australia. Here's the Part Nobody's Talking About.
Australia's TGA just cracked down on the illegal tanning shot this month — and the melanocortin receptor behind it also produced an FDA-approved medicine with a completely different story.
AOD-9604 Cleared the FDA's Ban List. The Phase 2 Data Didn't Change.
AOD-9604 cleared the FDA's Category 2 restricted list last month — the Phase 2b trial that ended development in 2007 has not changed.
CagriSema Didn't Beat Zepbound. Here's the Muscle Data Nobody's Talking About.
Cagrilintide lost the head-to-head with Zepbound in February. New body composition data from May changes what that means.
MOTS-c Is the Internet's Exercise Peptide. The FDA's July Review Asks About Obesity.
Biohackers call it 'exercise in a pill,' but the July PCAC docket lists MOTS-c for obesity and osteoporosis — not performance.
TB-500 Got the Same FDA Hearing Date as BPC-157. This One Is About Recovery.
TB-500 is on the same July PCAC docket as BPC-157 — and for once, the federal indication actually tracks with the recovery story.
BPC-157 Finally Got a Federal Review Date. The FDA Isn't Asking About Recovery.
The most searched recovery peptide on the internet has its first formal federal review scheduled for July — and the clinical indication the FDA is evaluating is ulcerative colitis, not tendon or tissue repair.
Semaglutide Got a Liver Disease Approval. The EASL Data This Week Changes What That Means.
Nine months after semaglutide became the first GLP-1 approved for a serious liver disease, new data being unveiled at EASL 2026 this week is expanding what that approval actually covers.
Sermorelin Is Suddenly Everywhere. The Reason Andrew Huberman Quit Is More Useful Than the Hype.
The growth hormone peptide that was never banned from compounding is the story this month — and Huberman's experience is the caveat everyone's missing.
Semax Just Got an FDA Review Date. The Case Being Made Is Not About Nootropics.
The peptide everyone in biohacking circles uses for focus just got its first formal U.S. regulatory review — for stroke and migraine, not cognitive enhancement.
Epitalon Just Got an FDA Review Date. The Case Being Made Is Not About Aging.
The longevity community's favorite tetrapeptide is formally scheduled for federal review this summer — and the stated clinical indication is insomnia, not telomere extension.
Ipamorelin Is Having a Moment. Here's the Part Nobody's Saying.
The GH secretagogue everyone wants back already had its FDA advisory committee review — and the 2024 vote wasn't good news.
The FDA Just Moved on GHK-Cu. The Internet Read It Wrong.
The copper peptide trending across TikTok this month got a real regulatory update in April — and the internet's read of it skipped every important detail.
Liraglutide Has a Generic Now. The FDA Just Said That Ends the Compounding Story.
The oldest GLP-1 weight-loss drug just got a generic and a regulatory crackdown in the same year.
Tirzepatide Just Beat Semaglutide in a Mortality Study. Here's the Part Nobody's Saying.
New data from Digestive Disease Week 2026 shows tirzepatide outperforming semaglutide on mortality and GI events — but the study design is doing more work than the headlines let on.
Retatrutide Just Broke the Weight-Loss Record. Then a New Side Effect Appeared.
The triple agonist just posted the strongest Phase 3 numbers in its class — and a skin-sensation side effect nobody predicted.
CJC-1295 vs Ipamorelin: What They Actually Do.
Two GH-axis peptides are often paired online, but they press different biological switches.
Semaglutide Changed Weight Loss. Here's the Biology.
GLP-1 receptor signaling, appetite circuitry, glucose context, and why approved use is different from gray-market imitation.
Research Peptides: The Label That Should Make You Slow Down.
A research label is not a quality seal. It is a signal to ask harder questions about approval, purity, claims, and human use.
TB-500: Recovery Peptide or Internet Myth?
A clean separation between thymosin beta-4 biology, TB-500 claims, and the evidence people actually need.
BPC-157 Is Everywhere. The Human Evidence Is Not.
The recovery peptide people talk about most is still carried by preclinical evidence, regulatory ambiguity, and a lot of extrapolation.